Global Vaccine Market Forecast to 2017
London (PRWEB) October 02, 2013 -- Of late, the vaccines market is burgeoning with immense activities. Big pharmaceutical companies like GSK, Pfizer, Merck etc. are struggling to maintain their revenue and operating incomes amidst patent cliffs of blockbuster drugs. In such a scenario, vaccines, which have high entry barriers for generic players and the potential to generate blockbuster sales, are increasingly alluring the players.
Besides, the market has also gained momentum due to the recent technological advances that now allow the manufacturing of high efficacy combination vaccines, providing protection from a plethora of diseases in one schedule. This has resulted in the introduction of several promising vaccines, actively promoted by health agencies and non-profit organizations to offer maximum immunization coverage, especially in the developing regions with high incidence rates of infectious diseases.
The report, “Global Vaccine Market Forecast to 2017” provides an extensive research and in-depth analysis of the current status and future outlook of the global vaccine market. The market, which stood at US$ 27.3 bllion in 2012, is expected to grow at a CAGR of around 12% during 2012-2017.
In the report, the vaccine market has been studied on three distinct levels: Regional, Therapeutic Category, and Company. For regional analysis, key vaccine markets that together constitute around 90% of the global market, have been profiled. Further, the market has been broken down into 16 distinct therapeutic categories and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth.
The study further delves into the business dynamics of the major players in industry. To provide a thorough understanding of a company’s business model, the company’s current and historical financials have been analyzed. Moreover, our team has also analyzed each company’s strengths and weaknesses along with its vaccine portfolio and pipeline that will help the reader to better position his company vis-à-vis competition. This will help the reader to gain a deeper insight into each key market player.
1. Analyst View
2. Research Methodology
3. Global Vaccine Market Outlook to 2017
4. Major Vaccines: Current and Future Market Analysis
4.1 Pneumococcal
4.2 Influenza
4.3 Cancer
4.4 Polio
4.5 Varicella
4.6 Rotavirus
4.7 Meningococcal
4.8 DTP
4.9 Hepatitis
4.10 Measles, Mumps, and Rubella (MMR)
4.11 Japanese Encephalitis
4.12 Tuberculosis
4.13 Malaria
4.14 Rabies
4.15 Typhoid
4.16 HIV
5. Key Geographical Markets
5.1 US
5.2 Europe
5.3 Japan
5.4 China
5.5 India
5.6 Brazil
6. Competitive Landscape
6.1 GSK
6.2 Sanofi-Pasteur
6.3 Pfizer
6.4 Merck
6.5 Novartis
6.6 Emergent Biosolutions
6.7 AstraZeneca Plc.
6.8 Baxter International Inc.
6.9 BioCSL (CSL Biotherapies)
6.10 Dendreon Corporation
6.11 Takeda Pharmaceutical Company Limited
6.12 Crucell
List of Figures:
Figure 3-1: Global - Vaccine Market (Billion US$), 2012-2017
Figure 4-1: Global - Causes of Deaths in Children (
Figure 4-2: Global - Pneumococcal Vaccine Market (Billion US$), 2012-2017
Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2012-2017
Figure 4-4: Global - Cancer Vaccine Market (Billion US$), 2012-2017
Figure 4-5: Global - Polio Vaccine Market (Billion US$), 2012-2017
Figure 4-6: Global - Varicella Vaccine Market (Billion US$), 2012-2017
Figure 4-7: Global - Rotavirus Vaccine Market (Billion US$), 2012-2017
Figure 4-8: Global - Meningococcal Vaccine Market (Billion US$), 2012-2017
Figure 4-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010)
Figure 4-10: Global - Number of Ntetanus Incidences by Region (2009 & 2010)
Figure 4-11: Global - Number of Ttetanus Incidences by Region (2009 & 2010)
Figure 4-12: Global - Number of Pertussis Incidences by Region (2009 & 2010)
Figure 4-13: Global - DTP Vaccine Market (Billion US$), 2012-2017
Figure 4-14: Global - Hepatitis Vaccine Market (Million US$), 2012-2017
Figure 4-15: Global - Number of Measles Incidences by Region (2009 & 2010)
Figure 4-16: Global - Number of Mumps Incidences by Region (‘000), 2009 & 2010
Figure 4-17: Global - Number of Rubella Incidences by Region (2009 & 2010)
Figure 4-18: Global - MMR Vaccine Market (Million US$), 2012-2017
Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2012-2017
Figure 4-20: Global - Sources for Funding in HIV Vaccine R&D (%), 2011
Figure 5-1: Global - Vaccine Market by Region (%), 2012
Figure 5-2: Global - Vaccine Market by Region (%), 2017
Figure 5-3: US - Vaccine Market (Billion US$), 2012-2017
Figure 5-4: Europe - Vaccine Market (Billion US$), 2012-2017
Figure 5-5: Japan - Vaccine Market (Billion US$), 2012-2017
Figure 5-6: China - Vaccine Market (Billion US$), 2012-2017
Figure 5-7: India - Share of Domestic Consumption and Exports in Vaccine Market (2010)
Figure 5-8: India - Vaccine Market (Billion US$), 2012-2017
Figure 5-9: Brazil - Vaccine Market (Billion US$), 2012-2017
Figure 6-1: Global - Share of Key Players in Vaccine Market (2012)
Figure 6-2: GSK - Revenue Breakup by Business Segment (%), 2012
Figure 6-3: GSK - Vaccine Revenue Breakup by Product (%), 2012
Figure 6-4: Sanofi-Pasteur - Revenue Breakup by Business Segment (%), 2012
Figure 6-5: Sanofi-Pasteur - Vaccine Revenue Breakup by Product (%), 2012
Figure 6-6: Pfizer - Revenue Breakup by Business Segment (%), 2012
Figure 6-7: Pfizer - Revenue Breakup by Biopharmaceuticals (%), 2012
Figure 6-8: Merck - Revenue Breakup by Business Segment (%), 2012
Figure 6-9: Merck - Pharmaceutical Division Revenue by Segment (%), 2012
Figure 6-10: Novartis - Revenue Breakup by Business Segment (%), 2012
Figure 6-11: AstraZeneca - Revenue Breakup by Therapy Area (%), 2012
Figure 6-12: Baxter International - Revenue Breakup by Business Segment (%), 2012
Figure 6-13: BioCSL - Revenue Breakup by Business Segment (%), 2012
Figure 6-14: Takeda Pharmaceutical - Revenue Breakup by Business Segment (%), 2012
Figure 6-15: Crucell - Revenue Breakup by Vaccine Type (%), 2010
List of Tables:
Table 4-1: Pneumococcal Vaccine Market - Key Players and Vaccines
Table 4-2: Key Pneumococcal Vaccines in Pipeline
Table 4-3: Influenza Vaccine Market - Key Players and Vaccines
Table 4-4: Key Influenza Vaccines in Pipeline
Table 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)
Table 4-6: Cancer Vaccine Market - Key Players and Vaccines
Table 4-7: Key Cancer Vaccines in Pipeline
Table 4-8: Polio Vaccine Market - Key Players and Vaccines
Table 4-9: Key Polio Vaccines in Pipeline
Table 4-10: Varicella Vaccine Market - Key Players and Vaccines
Table 4-11: Rotavirus Vaccine Market - Key Players and Vaccines
Table 4-12: Key Rotavirus Vaccines in Pipeline
Table 4-13: Meningococcal Vaccine Market - Key Players and Vaccines
Table 4-14: Key Meningococcal Vaccines in Pipeline
Table 4-15: DTP Vaccine Market - Key Players and Vaccines
Table 4-16: Key DTP Vaccines in Pipeline
Table 4-17: Hepatitis Vaccine Market - Key Players and Vaccines
Table 4-18: Key Hepatitis Vaccines in Pipeline
Table 4-19: MMR Vaccine Market - Key Players and Vaccines
Table 4-20: Key MMR Vaccines in Pipeline
Table 4-21: Japanese Encephalitis Vaccine Market - Key Players and Vaccines
Table 4-22: Key Japanese Encephalitis Vaccines in Pipeline
Table 4-23: Tuberculosis Vaccine Market - Key Players and Vaccines
Table 4-24: Key Tuberculosis Vaccines in Pipeline
Table 4-25: Key Malaria Vaccines in Pipeline
Table 4-26: Rabies Vaccine Market - Key Players and Vaccines
Table 4-27: Key Rabies Vaccines in Pipeline
Table 4-28: Typhoid Vaccine Market - Key Players and Vaccines
Table 4-29: Key Typhoid Vaccines in Pipeline
Table 4-30: Global - Number of HIV/AIDS Patients by Region (2009)
Table 4-31: Key HIV Vaccines in Pipeline
Table 5-1: China - Vaccine Classification
Table 5-2: China - Annual Pediatric Vaccine Doses Requirement (Million Doses)
Table 6-1: GSK - Vaccines Portfolio
Table 6-2: GSK - Vaccines in Pipeline
Table 6-3: GSK - Strengths and Weaknesses
Table 6-4: Sanofi-Pasteur - Vaccines Portfolio
Table 6-5: Sanofi-Pasteur - Vaccines in Pipeline
Table 6-6: Sanofi-Pasteur - Strengths and Weaknesses
Table 6-7: Pfizer - Vaccines Portfolio
Table 6-8: Pfizer - Vaccines in Pipeline
Table 6-9: Pfizer - Strengths and Weaknesses
Table 6-10: Merck - Vaccines Portfolio
Table 6-11: Merck - Vaccines in Pipeline
Table 6-12: Merck - Strengths and Weaknesses
Table 6-13: Novartis - Vaccines Portfolio
Table 6-14: Novartis - Vaccines in Pipeline
Table 6-15: Novartis - Strengths and Weaknesses
Table 6-16: Emergent Biosolutions - Vaccines Portfolio
Table 6-17: Emergent Biosolutions - Vaccines in Pipeline
Table 6-18: Emergent Biosolutions - Strengths and Weaknesses
Table 6-19: AstraZeneca - Vaccines Portfolio
Table 6-20: AstraZeneca - Vaccines in Pipeline
Table 6-21: AstraZeneca - Strengths and Weaknesses
Table 6-22: Baxter International - Vaccines Portfolio
Table 6-23: Baxter International - Vaccines in Pipeline
Table 6-24: Baxter International - Strengths and Weaknesses
Table 6-25: BioCSL - Vaccines Portfolio
Table 6-26: BioCSL - Strengths and Weaknesses
Table 6-27: Dendreon Corporation - Vaccines Portfolio
Table 6-28: Dendreon Corporation - Vaccines in Pipeline
Table 6-29: Dendreon Corporation - Strengths and Weaknesses
Table 6-30: Takeda Pharmaceutical - Vaccines Portfolio
Table 6-31: Takeda Pharmaceutical - Vaccines in Pipeline
Table 6-32: Takeda Pharmaceutical - Strengths and Weaknesses
Table 6-33: Crucell - Vaccines Portfolio
Table 6-34: Crucell - Vaccines in Pipeline
Table 6-35: Crucell - Strengths and Weaknesses
Read the full report:
Global Vaccine Market Forecast to 2017
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website:http://www.reportbuyer.com/
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article